An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...